Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push?

[1]  M. Shabbout,et al.  BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma , 2006, Oncogene.

[2]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[3]  W. Deppert,et al.  Transcription-independent pro-apoptotic functions of p53. , 2005, Current opinion in cell biology.

[4]  Muller Fabbri,et al.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.

[5]  K. Rai,et al.  Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Y. Lerenthal,et al.  Proapoptotic BID Is an ATM Effector in the DNA-Damage Response , 2005, Cell.

[8]  S. Korsmeyer,et al.  A Role for Proapoptotic BID in the DNA-Damage Response , 2005, Cell.

[9]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[10]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[11]  M. Lind,et al.  The expression of Bcl‐2 family proteins differs between nonsmall cell lung carcinoma subtypes , 2005, Cancer.

[12]  T. Kuwana,et al.  BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. , 2005, Molecular cell.

[13]  J. Castle,et al.  Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs , 2005, Nature.

[14]  Brian J. Smith,et al.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. , 2005, Molecular cell.

[15]  S. Korsmeyer,et al.  Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.

[16]  M. Murphy,et al.  p53 Moves to Mitochondria: A Turn on the Path to Apoptosis , 2004, Cell cycle.

[17]  Patrick Dumont,et al.  Mitochondrial p53 activates Bak and causes disruption of a Bak–Mcl1 complex , 2004, Nature Cell Biology.

[18]  Ziwei Huang,et al.  Synthesis and helical structure of lactam bridged BH3 peptides derived from pro-apoptotic Bcl-2 family proteins. , 2004, Bioorganic & medicinal chemistry letters.

[19]  Tullio Pozzan,et al.  Phosphorylation of BCL‐2 regulates ER Ca2+ homeostasis and apoptosis , 2004, The EMBO journal.

[20]  Maurizio Pellecchia,et al.  Rational Design and Real Time, In-Cell Detection of the Proapoptotic Activity of a Novel Compound Targeting Bcl-XL , 2004 .

[21]  Martin Schuler,et al.  Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis , 2004, Science.

[22]  S. Korsmeyer,et al.  Cell Death Critical Control Points , 2004, Cell.

[23]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[24]  John Calvin Reed,et al.  Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. , 2003, Cancer research.

[25]  Shaomeng Wang,et al.  Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. , 2003, Seminars in oncology.

[26]  John Calvin Reed,et al.  Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. , 2003, Journal of medicinal chemistry.

[27]  S. R. Datta,et al.  BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis , 2003, Nature.

[28]  P. Gaulard,et al.  Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). , 2003, Blood.

[29]  M. Minden,et al.  Bcl-2 and apoptosis in chronic lymphocytic leukemia , 2003, Current treatment options in oncology.

[30]  H. Pehamberger,et al.  Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. , 2003, The Journal of investigative dermatology.

[31]  J. D. Vos,et al.  A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells , 2003, Oncogene.

[32]  Tullio Pozzan,et al.  BAX and BAK Regulation of Endoplasmic Reticulum Ca2+: A Control Point for Apoptosis , 2003, Science.

[33]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Korsmeyer,et al.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. , 2002, Cancer cell.

[35]  R. Bataille,et al.  Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. , 2002, Blood.

[36]  Sridhar Ramaswamy,et al.  Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability , 2002, Cell.

[37]  John Calvin Reed,et al.  Dysregulation of apoptosis genes in hematopoietic malignancies , 2002, Oncogene.

[38]  W. Hahn,et al.  Modelling the molecular circuitry of cancer , 2002, Nature Reviews Cancer.

[39]  A. Strasser,et al.  Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins , 2002, Cell Death and Differentiation.

[40]  I. Gojo,et al.  Myeloid cell factor-1 is a critical survival factor for multiple myeloma. , 2002, Blood.

[41]  D. Green,et al.  A Matter of Life and Death , 2008, Science.

[42]  A. Jewell.  Role of apoptosis in the pathogenesis of B-cell chronic lymphocytic leukaemia , 2002, British journal of biomedical science.

[43]  X. Wang.  The expanding role of mitochondria in apoptosis. , 2001, Genes & development.

[44]  I. Enyedy,et al.  Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. , 2001, Journal of medicinal chemistry.

[45]  J. Chin,et al.  Design and Evolution of a Miniature Bcl-2 Binding Protein. , 2001, Angewandte Chemie.

[46]  S. Korsmeyer,et al.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. , 2001, Molecular cell.

[47]  K. Matsuzaki.  Why and how are peptide-lipid interactions utilized for self defence? , 2001, Biochemical Society transactions.

[48]  Xu Luo,et al.  Endonuclease G is an apoptotic DNase when released from mitochondria , 2001, Nature.

[49]  M. Minden,et al.  The BH3 domain of BAD fused to the Antennapedia peptide induces apoptosis via its alpha helical structure and independent of Bcl-2 , 2001, Cell Death and Differentiation.

[50]  W. Zong,et al.  BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. , 2001, Genes & development.

[51]  S. Korsmeyer,et al.  Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death , 2001, Science.

[52]  Kam Y. J. Zhang,et al.  Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3 , 2001, Nature Cell Biology.

[53]  T. Mitchison,et al.  Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL , 2001, Nature Cell Biology.

[54]  G. Kroemer,et al.  Permeabilization of the mitochondrial inner membrane during apoptosis: impact of the adenine nucleotide translocator , 2000, Cell Death and Differentiation.

[55]  S. Korsmeyer,et al.  The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. , 2000, Molecular cell.

[56]  Nico Tjandra,et al.  Structure of Bax Coregulation of Dimer Formation and Intracellular Localization , 2000, Cell.

[57]  J. Mai,et al.  Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  V. Mootha,et al.  tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. , 2000, Genes & development.

[59]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[60]  Robert L Moritz,et al.  Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins , 2000, Cell.

[61]  S. Srinivasula,et al.  Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[62]  M. Konopleva,et al.  Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. , 2000, Blood.

[63]  D. Cunningham,et al.  Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  Ralph Weissleder,et al.  Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells , 2000, Nature Biotechnology.

[65]  E. Alnemri,et al.  Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. , 2000, Cancer research.

[66]  T. Nakashima,et al.  Tetrocarcin A inhibits mitochondrial functions of Bcl-2 and suppresses its anti-apoptotic activity. , 2000, Cancer research.

[67]  S. Schwarze,et al.  In vivo protein transduction: delivery of a biologically active protein into the mouse. , 1999, Science.

[68]  Erkki Ruoslahti,et al.  Anti-cancer activity of targeted pro-apoptotic peptides , 1999, Nature Medicine.

[69]  J. Buolamwini.  Novel anticancer drug discovery. , 1999, Current opinion in chemical biology.

[70]  S. Korsmeyer,et al.  BCL-2 family members and the mitochondria in apoptosis. , 1999, Genes & development.

[71]  Jean-Claude Martinou,et al.  Bid-induced Conformational Change of Bax Is Responsible for Mitochondrial Cytochrome c Release during Apoptosis , 1999, The Journal of cell biology.

[72]  B. Corfe,et al.  Cell Damage-induced Conformational Changes of the Pro-Apoptotic Protein Bak In Vivo Precede the Onset of Apoptosis , 1999, The Journal of cell biology.

[73]  Ruedi Aebersold,et al.  Molecular characterization of mitochondrial apoptosis-inducing factor , 1999, Nature.

[74]  Junying Yuan,et al.  Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.

[75]  G. Packham,et al.  Mutation of BCL-2 Family Proteins in Cancer , 1998, Apoptosis.

[76]  H. Pehamberger,et al.  bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice , 1998, Nature Medicine.

[77]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[78]  J C Reed,et al.  Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.

[79]  E. Cheng,et al.  A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[80]  D C Linch,et al.  Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. , 1996, Blood.

[81]  A. Prochiantz,et al.  Cell Internalization of the Third Helix of the Antennapedia Homeodomain Is Receptor-independent* , 1996, The Journal of Biological Chemistry.

[82]  R. Lemieux,et al.  Role of bcl-X(L) in the control of apoptosis in murine myeloma cells. , 1996, Cancer research.

[83]  E. Cheng,et al.  Bax-independent inhibition of apoptosis by Bcl-XL , 1996, Nature.

[84]  D. Begley,et al.  The Blood‐brain Barrier: Principles for Targeting Peptides and Drugs to the Central Nervous System , 1996, The Journal of pharmacy and pharmacology.

[85]  J. Lee,et al.  Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[86]  M. Tomita,et al.  Absorption-enhancing mechanism of sodium caprate and decanoylcarnitine in Caco-2 cells. , 1995, The Journal of pharmacology and experimental therapeutics.

[87]  H. Joensuu,et al.  Bcl-2 protein expression and long-term survival in breast cancer. , 1994, The American journal of pathology.

[88]  A. Harris,et al.  bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. , 1994, British Journal of Cancer.

[89]  L. Larsson,et al.  The role of Bcl-2 in the pathogenesis of B chronic lymphocytic leukemia. , 1993, Leukemia & lymphoma.

[90]  M. Rowe,et al.  Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[91]  John Calvin Reed,et al.  bcl-2 Gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia , 1993 .

[92]  M. Campbell,et al.  Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. , 1992, Cancer research.

[93]  A. Frankel,et al.  Endocytosis and targeting of exogenous HIV‐1 Tat protein. , 1991, The EMBO journal.

[94]  T. McDonnell,et al.  Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18) , 1991, Nature.

[95]  A. Strasser,et al.  Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2 , 1990, Nature.

[96]  H V Westerhoff,et al.  Magainins and the disruption of membrane-linked free-energy transduction. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[97]  J. Sklar,et al.  Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[98]  C. Croce,et al.  The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. , 1985, Science.

[99]  S. Korsmeyer,et al.  Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18 , 1985, Cell.

[100]  V A Levin,et al.  Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. , 1980, Journal of medicinal chemistry.

[101]  G. Shore,et al.  Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. , 2005, Hematology. American Society of Hematology. Education Program.

[102]  V. Torchilin,et al.  Tat peptide-mediated intracellular delivery of liposomes. , 2003, Methods in enzymology.

[103]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[104]  T J Hamblin,et al.  B-cell chronic lymphocytic leukemia: a bird of a different feather. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  E. Matutes,et al.  bcl-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: a comparative study. , 1998, Haematologica.